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Objective: Whether intracerebral hemorrhage (ICH) associated with non–vitamin K antagonist oral anticoagulants
(NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain.
Methods: We performed a systematic review and individual patient data meta-analysis of cohort studies comparing
clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was
30-day all-cause mortality. All outcomes were assessed in multivariate regression analyses adjusted for age, sex, ICH
location, and intraventricular hemorrhage extension.
Results: We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age = 77 years,
52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs 26.5%; hazard ratio =
0.94, 95% conﬁdence interval [CI] = 0.67–1.31). However, in multivariate analyses adjusting for potential confounders,
NOAC-ICH was associated with lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regres-
sion coefﬁcient = −2.83, 95% CI = −5.28 to −0.38), lower likelihood of severe stroke (NIHSS > 10 points) on admis-
sion (odds ratio [OR] = 0.50, 95% CI = 0.30–0.84), and smaller baseline hematoma volume (linear regression
coefﬁcient = −0.24, 95% CI = −0.47 to −0.16). The two groups did not differ in the likelihood of baseline hematoma
volume < 30cm3 (OR = 1.14, 95% CI = 0.81–1.62), hematoma expansion (OR = 0.97, 95% CI = 0.63–1.48), in-hospital
mortality (OR = 0.73, 95% CI = 0.49–1.11), functional status at discharge (common OR = 0.78, 95% CI = 0.57–1.07), or
functional status at 3 months (common OR = 1.03, 95% CI = 0.75–1.43).
Interpretation: Although functional outcome at discharge, 1 month, or 3 months was comparable after NOAC-ICH
and VKA-ICH, patients with NOAC-ICH had smaller baseline hematoma volumes and less severe acute stroke
syndromes.
ANN NEUROL 2018;84:702–712
Intracerebral hemorrhage (ICH) is the most feared com-plication of oral anticoagulation, with mortality
approaching 50%.1 Despite advances in primary preven-
tion and especially the treatment of hypertension, the
global incidence of ICH has remained stable,2 in part due
to the increase of anticoagulant-related ICH in the
elderly.3
Use of oral anticoagulation with vitamin K antago-
nists (VKAs) is known to double the ICH risk even
under optimal treatment conditions (international nor-
malized ratio [INR] = 2–3); the annual risk of ICH is
estimated to range from 0.3 to 0.6% per year.4,5 Apart
from the increased incidence, VKA-associated ICH
(VKA-ICH) is associated with larger hematoma volumes,
increased case fatality, and poor functional outcome.6,7
Non–vitamin K antagonist oral anticoagulants (NOACs)
have similar efﬁcacy in ischemic stroke prevention in
patients with nonvalvular atrial ﬁbrillation (NVAF), with
half the incidence of ICH compared to warfarin.8
Although the pharmacodynamics, short half-life, and dis-
criminate anticoagulant action of NOACs have been
associated with the lower risk of incident ICH, ﬁndings
are conﬂicting regarding the outcome of patients with
NOAC-associated ICH (NOAC-ICH) compared to
VKA-ICH.9,10
We therefore performed a systematic review and
individual patient data meta-analysis (IPDM), including
data from available cohort studies comparing clinical and
radiological outcomes between NOAC-ICH and VKA-
ICH patients.
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Patients and Methods
Literature Search and Trial Identiﬁcation
This meta-analysis is presented according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses for Individual Patient Data (PRISMA-IPD)
guidelines11 and was written according to the Meta-
analysis of Observational Studies in Epidemiology pro-
posal.12 We followed a prespeciﬁed study protocol that
has been published in the International Register PROS-
PERO (International Prospective Register of Ongoing Sys-
tematic Reviews).13
Eligible study protocols reporting clinical and radio-
logical characteristics of NOAC-ICH in comparison to
VKA-ICH were identiﬁed by searching MEDLINE and
Scopus. The combination of search strings that was used
in all database searches included the terms “intracerebral
hemorrhage”, “intracranial hemorrhage”, “intracranial
bleeding”, “cerebral hemorrhage”, “cerebral hematoma”,
“vitamin K antagonists” (including also the names of all
pharmaceutical substances), “novel oral anticoagulants”,
“direct oral anticoagulants”, and “non-vitamin K antag-
onist oral anticoagulants” (including also the names of
all pharmaceutical substances). No language or other
restrictions were imposed. The last literature search was
conducted on August 25, 2017. Reference lists of all
articles that met our inclusion criteria and of relevant
review articles were examined to identify studies that
may have been missed by the initial database search.
Literature searches were performed by 2 independent
teams of reviewers (G.T. and A.H.K., D.W. and
D.J.W.), and emerging disagreements were resolved
with consensus.
Data Transfer and Veriﬁcation
Anonymized data were transferred from participating cen-
ters to the Coordinating and Data Management Centre
(National Hospital for Neurology and Neurosurgery,
Queen Square University College Hospitals, National
Health Service Foundation Trust). The data obtained
from each participating study were checked with respect
to range, internal consistency, consistency with pub-
lished reports, and missing items.14 Inconsistencies or
missing data were discussed with the individual princi-
pal investigators, and emerging problems were resolved
with consensus. Finally, data supplied were either
recoded or transformed to reﬂect common deﬁnitions
and common units of measurement across the generated
individual patient database, and computer-generated
detailed summary tabulations based on the converted
data were returned to each collaborator for review and
veriﬁcation.
Inclusion Criteria, Exclusion Criteria, and
Outcomes of Interest
To be eligible for inclusion in the IPDM, individual stud-
ies, registries, or databases (reported variously as prospec-
tive or retrospective observational cohort studies or trials)
were asked to include data available for compulsory base-
line characteristics of interest (age, sex, oral anticoagulant
agent, ICH location [lobar vs nonlobar], intraventricular
hemorrhage [IVH] extension in baseline neuroimaging)
and survival data (number of days from index event to
death). The list of noncompulsory variables that were
requested is available in Supplementary Table 1.
Hematoma volume was calculated with the same
method for NOAC-ICH and VKA-ICH using either the
ABC/2 method or planimetric measurement with adjust-
ments made for multilobar hemorrhage and scans with
nonuniform slice thickness.15 Hematoma expansion at
follow-up neuroimaging was deﬁned as an absolute
increase of >12.5cm3 or a relative increase of >33% in
hematoma volume at the follow-up scan compared to the
admission neuroimaging.16 In patients with sufﬁcient
data, we additionally calculated the corresponding
CHA2DS2-VASc scores,
17 if these were not provided in
the original databases.
In the present IPDM, we included patients older
than 18 years with diagnosis of acute primary ICH who
were conﬁrmed to be receiving VKAs (with INR > 1.5 on
admission)18 or NOACs (deﬁnite evidence of intake
within 24 hours before the ICH onset). We excluded
patients with ICH secondary to trauma (ie, major head
trauma thought to be sufﬁcient to have caused the ICH in
the previous 24 hours), vascular malformation, tumor,
cavernoma, aneurysm, or hemorrhagic transformation of
ischemic stroke. We additionally excluded patients with
primary subarachnoid hemorrhage (with or without an
ICH component), isolated intraventricular bleeding, and
VKA-ICH patients with INR ≤ 1.5 on admission.13
The primary outcome was 30-day all-cause mortality
between NOAC-ICH and VKA-ICH. Secondary outcomes
were admission stroke severity (assessed with the National
Institutes of Health Stroke Scale score [NIHSS]), severe
stroke (NIHSS > 10) on admission,19 level of consciousness
(quantiﬁed by Glasgow Coma Scale score [GCS]) on admis-
sion, hematoma volume on admission, small hematoma vol-
ume (<30cm3) on admission,20 hematoma expansion rate on
follow-up neuroimaging, in-hospital mortality, and func-
tional status at discharge and at 3 months, quantiﬁed by the
distribution of modiﬁed Rankin Scale (mRS) scores.
Quality Assessment in Included Studies
We used the Newcastle-Ottawa Scale to assess the quality
of each observational study that met our inclusion
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criteria.21 According to this scale, a maximum of 1 star
can be awarded for each item within the selection and
exposure/outcome categories and a maximum of 2 stars
for the comparability category; studies can earn a maxi-
mum of 9 star-points. Quality control and bias identiﬁca-
tion were performed by 2 independent reviewers (D.W.
and G.A.), and all disagreements were resolved with
consensus.21
Statistical Analysis
We summarized normally distributed continuous variables
as means with corresponding standard deviations, whereas
nonnormally distributed variables were reported as
medians with their corresponding interquartile ranges. All
categorical variables were presented as absolute numbers
with corresponding percentages.
Univariate Kaplan–Meier survival probabilities were
estimated for each anticoagulant group; the log-rank test
was used to compare groups. For the primary prespeciﬁed
outcome analysis, we ﬁtted a Cox proportional hazards
model with a frailty term for study. In this observational
study, the exposure (NOAC vs VKA) precedes acute ICH
and thus the exposure itself might affect some of the
markers of ICH severity (ICH volume and GCS). For
multivariate models of the outcome variables (mortality,
functional outcomes), we therefore only included covari-
ates that should not be affected by anticoagulant choice
(age, sex, ICH location, and IVH extension); we added a
shared frailty term to allow for possible site-related factors
(eg, general ICH management, resources, ethnicity). The
assumption of proportional hazards was assessed using
Schoenfeld residuals.
For the secondary outcomes of interest, we per-
formed mixed effects multivariate logistic or ordinal
regression analyses, as indicated. Anticoagulant (NOAC vs
VKA), age, sex, IVH extension, and ICH location were
treated as ﬁxed effects and registry as a random effect in
each analysis exploring clinical severity or functional out-
come/mortality, whereas anticoagulant (NOAC vs VKA),
age, sex, and ICH location were treated as ﬁxed effects
and registry as a random effect in the analysis exploring
ICH volume and ICH expansion. Associations in all logis-
tic and ordinal regression analyses are presented using
odds ratios (ORs) and common ORs (cORs), respectively,
with their corresponding 95% conﬁdence intervals
(CIs).13 In the ﬁnal multivariate analyses, statistical signiﬁ-
cance was achieved if 2-sided p < 0.05, calculated using
the likelihood ratio test. In multivariate models, we
excluded patients with missing data from the analysis; we
did not impute missing data.
Where applicable, the adjusted individual study
results were displayed using a forest plot and a 2-stage
meta-analysis was performed to calculate I2, a measure of
heterogeneity across studies, and τ2, a measure of variance
of the true effect sizes.22 The pooled estimate was sup-
pressed in these plots, because their sole purpose here is to
display the results from each individual study.
Finally, we performed prespeciﬁed subgroup analyses
on the primary outcome according to the NOAC drug
used (apixaban, dabigatran, rivaroxaban), reporting the rel-
evant p value for interaction for each one.
Results
Study Selection and Study Characteristics
Systematic search of MEDLINE and Scopus databases
yielded 600 and 684 results, respectively. After removing
duplicates, the titles and abstracts from the remaining
974 studies were screened and 12 potentially eligible stud-
ies for the meta-analysis were retained. After retrieving the
full-text version of the aforementioned 12 studies, 3 studies
were excluded because they included patients with trau-
matic brain injury23–25 and 1 study due to the lack of a
VKA-ICH comparator group (Supplementary Table 2).26
In the ﬁnal presentation of the literature search results,
there was no conﬂict or disagreement between the
reviewers and the corresponding authors from the 8 studies
that met the protocol’s inclusion criteria were contacted
by email. Individual patient data were obtained from all
study protocols, except for one,27 and the 7 eligible stud-
ies were ﬁnally included in the qualitative and quantitative
synthesis (Fig 1).28–34
Prior to applying our own inclusion and exclusion
criteria, we received 100% of expected patient numbers
from each study (Supplementary Table 3). No important
issues with IPD integrity were identiﬁed after checks
according to PRISMA checklist recommendations. Qual-
ity assessment of included studies highlighted one study32
that reported enrollment of some VKA patients before the
start of enrollment of their ﬁrst NOAC patient
(Supplementary Table 4).
After excluding 74 patients on a VKA with an initial
INR value ≤1.5, we were left with a total of 1,050 patients
(219 on NOACs and 831 on a VKA) from 7 individual
studies. Baseline characteristics and outcomes of the total
1,050 eligible ICH patients (NOAC-ICH, n = 219;
VKA-ICH, n = 831; mean age = 77 years, 52.5%
women) are summarized in Supplementary Table 5. The
use of any reversal strategy was approximately 3 times
more common (p < 0.001) in VKA-ICH patients
(n = 621, 89%) compared to NOAC-ICH patients
(n = 58, 31%). More speciﬁcally, use of vitamin K was
reported in 25% and 75% of NOAC-ICH and VKA-
ICH patients, respectively. Protein complex concentrate
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was used in 21% and 79% of NOAC-ICH and VKA-
ICH patients, whereas fresh frozen plasma was used in
22% and 78% of NOAC-ICH and VKA-ICH patients,
respectively. Use of a speciﬁc reversal agent (idarucizumab)
was reported in only one patient with NOAC-ICH.33
Primary Analysis
Two studies had follow-up times that were too short to
allow inclusion into our primary outcome of 30-day mor-
tality. Therefore, our primary analysis comprised
909 patients from 5 studies. In survival analysis, adjusting
for age, sex, ICH location, and IVH extension as well as
clustering by center, NOAC-ICH and VKA-ICH patients
did not differ in the risk of 30-day mortality (24.3% vs
26.5%; adjusted hazard ratio [HR] = 0.94, 95%
CI = 0.67–1.31, p = 0.702; Fig 2, Supplementary
Table 6). The proportional hazard assumption was not
violated (global test p = 0.247). Unadjusted Kaplan–Meier
plots for each included study on the primary outcome of
30-day mortality are available in Figure 3.
In a post hoc sensitivity analysis, including the
74 VKA-ICH patients with INR values ≤1.5 and the
patients from the 2 centers with short follow-up times
FIGURE 1: Flow chart presenting the selection of eligible studies. TBI = traumatic brain injury; VKA = vitamin K antagonist.
FIGURE 2: Cox regression analyses adjusted for each included
study on the primary outcome of 30-day mortality between
patients receiving pretreatment with non–vitamin K antagonist
oral anticoagulants and patient receiving treatment with vitamin
K antagonist oral anticoagulants. [Color ﬁgure can be viewed at
www.annalsofneurology.org]
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TABLE 1. Overview of Primary and Secondary Adjusted Analyses
Outcome Studies, n Patients, n Effect Size for NOAC (95% CI) p
Primary outcome
30-day mortality 5 909 HR = 0.94 (0.67 to 1.31) 0.702
30-day mortality, sensitivity analysisa 7 1,098 HR = 0.90 (0.66 to 1.21) 0.476
Secondary outcomes
Admission NIHSS 4 398 LRC = −2.83 (−5.28 to −0.38) 0.024
Admission NIHSS > 10 4 398 OR = 0.50 (0.30 to 0.84) 0.009
Baseline GCS 4 845 LRC = −0.01 (−0.57 to 0.55) 0.979
Baseline ICH volumeb 7 1,006 LRC = −0.24 (−0.47 to −0.16) 0.036
Baseline hematoma volume < 30 cm3b 7 1,006 OR = 1.14 (0.81 to 1.62) 0.447
Hematoma expansionb 7 617 OR = 0.97 (0.63 to 1.48) 0.883
In-hospital mortality 6 824 OR = 0.73 (0.49 to 1.11) 0.140
mRS at hospital discharge 6 824 cOR = 0.78 (0.57 to 1.07) 0.127
mRS at 90 days 3 748 cOR = 1.03 (0.75 to 1.43) 0.842
aIncluding the 74 vitamin K antagonist–ICH patients with international normalized ratio values ≤ 1.5 and after imputation of the patients from 2 cen-
ters with short follow-up times.
bAdjusted for age, sex, and ICH location. The remainder adjusted for age, sex, intraventricular hemorrhage extension, and ICH location.
CI = conﬁdence interval; cOR = common odds ratio; GCS = Glasgow Coma Scale; HR = hazard ratio; ICH = intracerebral hemorrhage; LRC = lin-
ear regression coefﬁcient; mRS = modiﬁed Rankin Scale; NIHSS = National Institutes of Health Stroke Scale; NOAC = non–vitamin K antagonist
oral anticoagulant; OR = odds ratio.
FIGURE 3: Unadjusted Kaplan–Meier plots for each included study on the primary outcome of 30-day mortality. NOAC = non–
vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist. [Color ﬁgure can be viewed at www.annalsofneurology.org]
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(after imputation of missing baseline values), we docu-
mented similar results for the risk of 30-day mortality
between NOAC-ICH and VKA-ICH patients
(HR = 0.90, 95% CI 0.66–1.21, p = 0.476; see Table 1).
Secondary Outcomes
Results of adjusted analyses on secondary outcomes of
interest are presented in Table 1 and Supplementary
Tables 7 to 15. An overview of unadjusted analyses on the
primary and secondary outcomes of interest is provided in
Supplementary Table 16 and Figure 4. Four studies com-
prising 398 patients had information available on NIHSS.
NOAC-ICH was associated with lower admission NIHSS
scores (adjusted linear regression coefﬁcient = −2.83,
95% CI = −5.28 to −0.38) and a lower likelihood of
severe stroke (NIHSS > 10 points) on admission (adjusted
OR = 0.50, 95% CI = 0.30–0.84).
Four studies comprising 845 patients had data avail-
able on GCS. In adjusted analysis, the two groups did not
differ on GCS on hospital admission (adjusted linear
regression coefﬁcient = −0.01, 95% CI = −0.57 to 0.55).
Seven studies comprising 1,006 patients had data
available on ICH volume. NOAC-ICH was associated
with smaller baseline hematoma volumes on admission
(adjusted linear regression coefﬁcient = −0.24, 95% CI =
−0.47 to −0.16). However, the odds of admission hema-
toma volume being <30cm3 did not differ between the
groups (adjusted OR = 1.14, 95% CI = 0.81–1.62)
Seven studies comprising 617 patients had data
available on ICH expansion on follow-up neuroimaging,
which did not differ between the two groups (adjusted
OR = 0.97, 95% CI = 0.63–1.48).
Seven studies comprising 902 patients had data on
in-hospital mortality and mRS at discharge. However, one
of the studies did not collect data on IVH extension and
thus could not be included in multivariate analysis. In
adjusted analysis comprising 824 patients from 6 studies,
no signiﬁcant differences between the two groups were
found regarding in-hospital mortality (adjusted OR =
0.73, 95% CI = 0.49–1.11) and functional status at hos-
pital discharge (adjusted cOR per 1-point increase in
mRS-score = 0.78, 95% CI = 0.57–1.07).
Three studies comprising 748 patients had data
available on 90-day mRS, which again shows no statistical
difference between the groups (adjusted cOR = 1.03,
95% CI = 0.75–1.43).
Analysis of individual NOAC drug type (Table 2)
revealed no signiﬁcant differences in their 30-day mortal-
ity risk compared with VKAs (apixaban: adjusted
HR = 0.56, 95% CI = 0.20–1.51; dabigatran: adjusted HR =
0.69, 95% CI = 0.34–1.40; rivaroxaban: adjusted HR = 1.11,
95% CI = 0.78–1.68; overall p = 0.267; Fig 5).
Discussion
Our IPDM showed comparable 30-day mortality rates
after NOAC-ICH and VKA-ICH, with no statistically sig-
niﬁcant differences in risk for different NOAC agents.
However, NOAC-ICH was independently associated with
less severe acute ICH as measured by baseline hematoma
volume and stroke severity (NIHSS) on admission. VKA-
ICH and NOAC-ICH had similar functional outcome at
discharge and at 3-month follow-up.
Our ﬁndings highlighting similar outcomes in
NOAC-ICH and VKA-ICH patients differ from those
reported from a recent retrospective analysis from the Get
with the Guidelines–Stroke (GWTG-Stroke) registry,
including 141,311 total ICH patients admitted to 1,662
US hospitals, suggesting that NOAC-ICH patients have
lower risk of in-hospital mortality and functional disability
at discharge compared to VKA-ICH patients.35 This dis-
parity could be attributed to the more stringent deﬁnition
of oral anticoagulant–related ICH in patients from our
cohort compared to that used in the cohort from the
GWTG-Stroke registry (any use of oral anticoagulant
within 7 days prior to hospital arrival) and the lack of
adjustment for baseline stroke severity in the multivariate
models of in-hospital mortality and functional outcome in
both GWTG-Stroke registry and our protocol.35 Our
study provides an invaluable insight in the anticoagulant-
related ICH neuroimaging outcomes, which are known to
be signiﬁcant predictors of clinical outcomes but in turn
are less affected by demographic characteristics compared
to clinical outcomes. Considering that demographic char-
acteristics have been inadequately assessed in our study
FIGURE 4: Unadjusted Kaplan–Meier curves on the probability of
30-day survival between patients with intracerebral hemorrhage
related to non–vitamin K antagonist oral anticoagulants (NOACs)
and patients with intracerebral hemorrhage related to vitamin
K antagonist (VKA) oral anticoagulants. [Color ﬁgure can be
viewed at www.annalsofneurology.org]
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protocol and in the study by Inohara et al,35 the impor-
tance of ﬁndings on neuroimaging outcomes is further
highlighted. We also consider that the results from the
current IPDM, incorporating data from international mul-
ticenter cohorts, are likely to be more easily generalizable
to every clinical setting. Finally, it should be noted that
ﬁndings from a very recent meta-analysis of available ran-
domized clinical trials on the use of NOACs for the pre-
vention of thromboembolism in patients with NVAF,
suggesting similar case fatality rates in NOAC-related and
VKA-related ICH,36 corroborate further our results on the
similar 30-day mortality risk between NOAC- and VKA-
related ICH patients and contradict further the ﬁnding of
lower in-hospital mortality risk for NOAC-ICH patients
reported in the study by Inohara et al.35
Our results are also in accordance with a previously
published systematic review and pairwise meta-analysis of
aggregate level data from 12 observational studies
(393 NOAC-ICH and 3,482 VKA-ICH), suggesting no
signiﬁcant differences in hematoma expansion, mortality,
and functional outcome between NOAC-ICH and VKA-
ICH patients.36 A nonsigniﬁcant association for lower
baseline ICH volume in NOAC-ICH compared to VKA-
ICH was also reported in this meta-analysis (standardized
mean difference = −0.24, 95% CI −0.52 to 0.04,
p = 0.093), whereas the association of NOAC-related
ICH with 30-day mortality was not evaluated in this
meta-analysis.37
The ﬁnding of lower baseline hematoma volumes in
NOAC-ICH compared to VKA-ICH could be attributed
to the more favorable pharmacological properties of
NOACs, including shorter plasma half-life and selective
inhibition of the extrinsic coagulation pathway, compared
to VKAs.38 The one-to-one direct stoichiometric inhibi-
tion of thrombin or factor Xa by NOACs favors the phys-
iological cerebrovascular hemostatic response after an
ICH, in contrast to the impaired hemostasis due to
thrombin substrate deﬁciency induced by VKAs.39 How-
ever, although hematoma volume on admission is associ-
ated with stroke severity40 and long-term outcome after
an ICH,41 we detected no signiﬁcant differences between
NOAC-ICH and VKA-ICH patients in 30-day mortality
risk, the rate of hematoma expansion, in-hospital mortal-
ity, or functional outcome at discharge and 3-month
follow-up. Because the trajectory of recovery of ICH
might be slower than that after ischemic stroke,42 it is pos-
sible that with longer follow-up the apparent beneﬁts of
NOACs on acute ICH volume and stroke severity might
TABLE 2. Adjusted Subgroup Analysis on the Primary Outcome of 30-Day Mortality according to the Type of
Non–Vitamin K Oral Anticoagulant Based on 5 Studies and 909 Patients
HR 95% CI p
VKA Baseline — —
Rivaroxaban 1.11 0.78–1.68 0.494
Dabigatran 0.69 0.34–1.40 0.300
Apixaban 0.56 0.20–1.51 0.249
Age, per year increase 1.02 1.01–1.04 0.006
Sex, female/male 1.13 0.87–1.46 0.370
IVH, yes/no 3.16 2.39–4.16 <0.001
ICH location, lobar/nonlobar 1.19 0.91–1.55 0.211
CI = conﬁdence interval; HR = hazard ratio; ICH = intracerebral hemorrhage; IVH = intraventricular hemorrhage extension; VKA = vitamin K
antagonist.
FIGURE 5: Subgroup analysis on the risk of 30-day mortality
in patients with intracerebral hemorrhage related to the use
of different non–vitamin K antagonist oral anticoagulants.
Overall p = 0.267. VKA = vitamin K antagonist. [Color ﬁgure
can be viewed at www.annalsofneurology.org]
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translate into better functional outcome. Longer term
studies of outcome after VKA-ICH and NOAC-ICH will
be needed to investigate this possibility.
Our study has strengths. We included a large sample
of individual participant data, allowing us to perform
adjusted analyses for both clinical and radiological out-
comes between NOAC-ICH and VKA-ICH. We included
high-quality observational studies, using prespeciﬁed
inclusion criteria at both study and individual patient
level. However, there are also several limitations that
should be taken into consideration. First, individual par-
ticipant data from one study including 27 participants was
not available,27 but we consider the potential impact of
this to be negligible. Second, although we collected
detailed baseline data, we were not able to assess and fur-
ther adjust the potential impact of some clinical (eg, the
degree of blood pressure reduction),43 laboratory (eg, cho-
lesterol levels on admission),44 and neuroimaging (eg,
presence of cerebral microbleeds or cortical superﬁcial
siderosis)45–48 parameters on the outcomes of interest. It
should also be noted that there was no central adjudica-
tion in image analysis for both baseline and follow-up
neuroimaging scans. Moreover, because patients in the
two groups were not randomized to NOAC or VKA
administration, imbalances in both baseline characteristics
and other potential confounders, including onset-to-
neuroimaging time,49 could be present. Despite adjust-
ment for baseline factors, there is also a risk of residual
confounding by indication, which is not completely
addressed in the current IPDM or in the previous report
from the GWTG-Stroke registry.35 Moreover, it should
also be noted that we were unable to assess for the tempo-
ral and geographical differences in ICH care or practice
patterns, including the choice and administration timing
of reversal agents, which are known to inﬂuence ICH out-
comes. Due to the complexity of reasons for clinician
selection of an anticoagulant regimen for particular
patients and the presence of signiﬁcant disparities in ICH
management, we consider that only randomized controlled
trial data will be able to ﬁrmly account for these potential
biases.
The availability of reversal strategies for oral antico-
agulants and the timing of their administration after ICH
onset could also account for potential difference in out-
comes between NOAC-ICH and VKA-ICH patients in
the present IPDM. The use of any reversal strategy was
approximately 3 times more common in VKA-ICH than
in NOAC-ICH cases. Given that NOAC-speciﬁc reversal
agents may be associated with a lower case fatality rate in
NOAC-related ICH,36 the more widespread future use of
these agents might result in a substantial decrease of
NOAC-ICH mortality.
Due to the lack of signiﬁcant differences in clinical
outcomes between NOAC-ICH and VKA-ICH, despite
the disparities in neuroimaging ﬁndings, we performed a
post hoc power calculation to investigate for the possibility
of a ceiling effect and underpowering; this indicated that
our IPDM had 80% power to detect a 10% absolute dif-
ference (and a corresponding HR of 0.56) for the primary
outcome of interest (30-day mortality) between NOAC-
ICH and VKA-ICH patients. Thus, our IPDM was not
powered to detect smaller differences in the 1-month mor-
tality rates between NOAC-ICH and VKA-ICH patients.
We note that the adjusted absolute risk difference in the
in-hospital mortality that was detected in the GWTG-
Stroke registry was 6%.35 The missing functional evalua-
tions in 20% and 30% of our study population at dis-
charge and at 3 months may have diluted the potential
beneﬁcial effect of NOACs on functional outcomes in
ICH patients, but these were secondary outcomes.
Because premorbid mRS scores were not available in the
included study protocols, the lack of signiﬁcant differences
on clinical outcomes could also be attributed to the inabil-
ity for adjustment for the presence of disability prior to
index event. Finally, as in the primary analysis, we con-
sider the subgroup analysis according to NOAC regimen
underpowered and the risk of residual confounding in the
NOAC-ICH subgroup possible.
In conclusion, our IPDM provides preliminary evi-
dence that although 30-day clinical outcomes appear to be
comparable between NOAC-ICH and VKA-ICH
patients, NOAC-ICH may be related to lower baseline
hematoma volumes and lower admission stroke severity
scores. This observation requires independent conﬁrma-
tion in larger prospective cohort studies adjusting for all
potential confounders, including neuroimaging parameters
and pre-ICH functional status. Longer term follow-up
studies should determine whether outcomes beyond
30 days differ between VKA-ICH and NOAC-ICH.
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